Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (NASDAQ: REPL) is a clinical-stage biotechnology company committed to advancing cancer treatment through innovative oncolytic immune-gene therapies. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune leverages its proprietary Immulytic™ platform to develop product candidates aimed at activating the immune system against solid tumors.
The core of Replimune’s portfolio includes RP1, RP2, and RP3, all based on genetically-engineered strains of herpes simplex virus 1 (HSV-1). These strains are modified to maximize tumor killing and stimulate a systemic anti-tumor immune response. RP1, the company’s lead product, is designed for enhanced tumor killing and has shown promising results in combination with anti-PD1 therapies. It is currently undergoing clinical trials for anti-PD1 failed melanoma and other skin cancers, with plans to submit a Biologics License Application (BLA) in 2H 2024.
Another notable candidate is RP2, which expresses an anti-CTLA-4 antibody-like protein to further enhance immune response. RP2 has demonstrated durable response rates in advanced uveal melanoma patients, a particularly challenging cancer type with limited treatment options. RP3, the third candidate in the pipeline, is engineered to express multiple immune-activating proteins, though its development has currently been paused to focus on higher priority programs.
Replimune's recent achievements include favorable safety profiles and substantial response rates in clinical trials. For instance, RP2 in combination with nivolumab showed a durable overall response rate of nearly 30% in patients with metastatic uveal melanoma. Additionally, RP1 has demonstrated significant anti-tumor activity in organ transplant recipients who typically cannot undergo systemic immunotherapy.
The company has established alliances with major pharmaceutical entities, such as Regeneron Pharmaceuticals, to further its clinical trials and explore combination therapies. Financially, Replimune is robust, with a cash runway extending into early 2026, thanks to strategic reprioritization and successful capital management.
Replimune is dedicated to evolving its portfolio and optimizing its RPx platform. The dual local and systemic mechanism of action of its therapies offers a versatile approach that can be combined with various other cancer treatment modalities, thus holding significant promise for the future of oncology.
Replimune Group, Inc. (Nasdaq: REPL) has announced a public offering of 4,687,500 shares at $40.00 per share, raising approximately $250 million before expenses. Additionally, the company will offer pre-funded warrants for 1,562,500 shares at $39.9999 each. The offering is expected to close on October 26, 2020. J.P. Morgan, SVB Leerink, and Barclays act as joint book-running managers. This follows a previously filed shelf registration statement with the SEC. The funds raised aim to support the company’s oncolytic immuno-gene therapy development.
Replimune Group, Inc. (Nasdaq: REPL) announced a proposed public offering of $125 million in common stock, with a potential 30-day option for underwriters to purchase an additional $18.75 million. The offering is to be managed by J.P. Morgan and SVB Leerink, subject to market conditions. Proceeds are intended to support Replimune's development of its oncolytic immuno-gene therapies derived from the Immulytic™ platform. This press release is not an offer to sell securities and will be filed with the SEC.
Replimune Group, Inc. (NASDAQ: REPL) has filed a Current Report on Form 8-K to update its corporate presentation, now available on their website. The updated presentation includes key information regarding abstracts to be showcased at the 2020 Society for Immunotherapy of Cancer Annual Meeting, featuring clinical trial data updates. Notably, data from these abstracts was accidentally released on October 14, 2020. Replimune's Immulytic™ platform focuses on developing oncolytic immuno-gene therapies aimed at enhancing cancer treatment through immune response activation.
Replimune Group, Inc. (NASDAQ: REPL) announced the appointment of Tanya Lewis to its Board of Directors, effective November 2, 2020. With over 20 years in global drug development, particularly in oncology, her expertise enhances Replimune's regulatory strategies. Previously, she held significant roles at Karyopharm Therapeutics, Tesaro, and Millennium, where she drove successful drug approval processes. This appointment aims to strengthen Replimune's efforts to bring their oncolytic immunotherapies to market amid a growing pipeline.
Replimune Group Inc. (NASDAQ: REPL) announced the initial safety and efficacy data of its oncolytic immuno-gene therapy candidates, RP1 and RP2, during the Society for Immunotherapy of Cancer (SITC) virtual meeting. The Phase 1 trial of RP2 indicated promising results with 50% of patients showing ongoing partial responses. The RP1 trial also demonstrated positive outcomes, including a response rate of 87.5% in non-melanoma skin cancers. Both therapies exhibited manageable safety profiles, supporting further clinical study.
Replimune Group Inc. (Nasdaq: REPL) announces that CEO Philip Astley-Sparke will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:30 a.m. ET. Replimune is a biotechnology company based in Woburn, MA, specializing in developing oncolytic immuno-gene therapies through its Immulytic™ platform. This innovative approach aims to enhance the immune response to tumors and improve cancer treatment efficacy, particularly in conjunction with immune checkpoint blockade therapies.
Replimune Group, a biotechnology firm, announced a public offering of 2,826,088 shares of common stock at $23.00 per share, along with pre-funded warrants for 1,521,738 shares at $22.9999 each. The total gross proceeds are estimated at $100 million, excluding underwriting discounts. The offering is set to close on June 11, 2020, pending customary conditions. J.P. Morgan, SVB Leerink, and BMO Capital act as joint managers. This offering aims to fund ongoing development of Replimune's oncolytic immuno-gene therapies derived from its Immulytic platform.
Replimune Group, Inc. (Nasdaq: REPL) announced a proposed public offering of $80 million in common stock, alongside pre-funded warrants for certain investors. The offering includes a 30-day option for underwriters to purchase an additional $12 million in shares. The offering is subject to market conditions and customary closing criteria. J.P. Morgan Securities LLC, SVB Leerink LLC, and BMO Capital Markets Corp. are the joint book-running managers. All sales will be conducted under a previously filed shelf registration statement.
Replimune Group, Inc. (NASDAQ: REPL) reported fiscal Q4 and year-end financial results as of March 31, 2020. The net loss was $15.8 million for Q4 and $52.6 million for the fiscal year, an increase from $6.7 million and $30.8 million in the prior year. Cash and equivalents increased to $168.6 million from $134.8 million. Clinical updates revealed promising data for RP1 in treating cutaneous squamous cell carcinoma and melanoma. The firm is set to expand its clinical development into non-small cell lung cancer (NSCLC) and has completed a new manufacturing facility.
FAQ
What is the current stock price of Replimune Group (REPL)?
What is the market cap of Replimune Group (REPL)?
What is Replimune Group, Inc.?
What is the Immulytic™ platform?
What are Replimune’s main product candidates?
What recent achievements has Replimune made?
What are the clinical goals for RP1?
How does RP2 differ from RP1?
What is the financial outlook for Replimune?
What partnerships does Replimune have?
What is the RPx platform?
What are Replimune's future plans?
